Please wait while the transcript is being prepared...
0:00
Welcome to this lecture on
clinical pharmacology during
pregnancy and lactation.
I'm Karel Allegaert.
I'm a clinician-researcher
working
at Rotterdam University
as well as KU Leuven.
0:14
The overarching learning
objective of this lecture is to
highlight the specific
characteristics
related to both pharmacokinetics
and pharmacodynamics and related
to these pharmacodynamics
also aspects related
to safety for mother, fetus
and potentially
lactating infant.
As we all know, a given dose
will result in a
given concentration
in a compartment in the body;
most commonly studied is
obviously the blood compartment.
This concentration
will subsequently
result in a given effect
and that's what makes
a difference between
pharmacokinetics and
pharmacodynamics.
Obviously, pregnancy
in itself will have
a major impact on drug handling
and potentially also
on drug effects.
This is the focus or
the learning objective
of this lecture.
1:01
As I already somewhat alluded to
there is extensive variability.
This means that the
pharmacokinetics and/or
pharmacodynamics may change
significantly
throughout pregnancy.
An important message hereby is
that pregnancy in itself is
not a dichotomous covariant.
As for instance,
consecutive trimesters of
pregnancy may have
different impacts
on drug handling
or drug effects.
To somewhat further
extent, the idea
initially raised on children and
their specific characteristics
to study drugs.
The child is not just a small
adult and the newborn is not
just a small child
along the same way
pregnant woman is not just
a woman with a big belly.
